NCT06592768

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Jasper Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model. A single dose proof of concept approach at a dose level shown to be biologically active should inform the impact of briquilimab on allergic asthma as compared to placebo while minimizing exposure to participants, in a new indication.

Conditions

• Allergic Asthma

Interventions

Type	Name	Description
DRUG	Briquilimab	Subcutaneous Administration
OTHER	Placebo Comparator	Subcutaneous Administration

Timeline

• Start date: 2024-11-26
• Primary completion: 2025-08-11
• Completion: 2025-08-11
• First posted: 2024-09-19
• Last updated: 2025-09-16

Locations

6 sites across 1 country: Canada